Evidence map›Paper›PMID 40563570›Full record

ArticleCancers2025

The RXR Agonist MSU-42011 Reduces Tumor Burden in a Murine Preclinical NF1-Deficient Model.

Pei-Yu Hung, Jessica A Moerland, Ana S Leal, Bilal Aleiwi, Edmund Ellsworth, D Wade Clapp, Verena Staedtke, Renyuan Bai, Karen T Liby

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pei-Yu HungDepartment of Physiology, Michigan State University, East Lansing, MI 48824, USA.
Jessica A MoerlandDepartment of Pediatrics and Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA.ORCID 0000-0002-8085-3470
Ana S LealDepartment of Medicine, Divisions of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Bilal AleiwiDepartment of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824, USA.
Edmund EllsworthDepartment of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824, USA.
D Wade ClappDepartment of Pediatrics and Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Verena StaedtkeDepartment of Neurology, Johns Hopkins University, Baltimore, MD 21287, USA.
Renyuan BaiKennedy Krieger Institute, Baltimore, MD 21205, USA.ORCID 0000-0001-5281-9091
Karen T LibyDepartment of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824, USA.ORCID 0000-0003-3317-3437

Funding

Falk trust 4487555
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

malignant peripheral nerve sheath tumors (MPNSTs)neurofibromatosis type 1plexiform neurofibromas (PNFs)retinoid X receptor (RXR) agonistselumetinib

Identifiers

PMID40563570
PMCPMC12190937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.